Hypoxia induces calpain activity and degrades SMAD2 to attenuate TGFβ signaling in macrophages

Cell and Bioscience

Volumn 5, Issue 1, 2015, Pages

  Cui, Wei ^a,b   Zhou, Jie ^a   Dehne, Nathalie ^b   Brüne, Bernhard ^b  

^a BEIJING NORMAL UNIVERSITY   (China)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Calpain; Hypoxia; Macrophages; phospho SMAD2; SMAD2 degradation; TGF

Indexed keywords

EID: 85027952129     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/s13578-015-0026-x     Document Type: Article

References (52)

1. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20.
2. Weigert A, Brüne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide. 2008;19(2):95-102.
3. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113(6):685-700.
4. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425(6958):577-84.
5. Nurgazieva D, Mickley A, Moganti K, Ming W, Ovsyi I, Popova A, et al. TGF-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes. J Immunol. 2015;194(2):709-18.
6. Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788-99.
7. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol. 2010;10(8):554-67.
8. Gong D, Shi W, Yi S-j, Chen H, Groffen J, Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13(1):31.
9. Gigante M, Gesualdo L, Ranieri E. TGF-beta: a master switch in tumor immunity. Curr Pharm Des. 2012;18(27):4126-34.
10. Byrne SN, Knox MC, Halliday GM. TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol. 2007;86(1):92-7.
11. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-7.
12. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47.
13. Ratcliffe PJ. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol. 2013;591(8):2027-42.
14. Brüne B, Dehne N, Grossmann N, Jung M, Namgaladze D, Schmid T, et al. Redox control of inflammation in macrophages. Antioxid Redox Signal. 2013;19(6):595-637.
15. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology. 2012;55(2):622-33.
16. Ueno M, Maeno T, Nomura M, Aoyagi-Ikeda K, Matsui H, Hara K, et al. Hypoxia-inducible factor-1aα mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011;300(5):L740-52.
17. Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, Schnaper HW. Interdependence of HIF-1aα and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol. 2011;300(4):F898-905.
18. Chae K, Kang M, Lee J, Ryu B, Lee M, Her N, et al. Opposite functions of HIF-aα isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions. Oncogene. 2011;30(10):1213-28.
19. Herr B, Zhou J, Werno C, Menrad H, Namgaladze D, Weigert A, et al. The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1aα in macrophages via sphingosine-1-phosphate and transforming growth factor-β. Blood. 2009;114(10):2140-8.
20. Dehne N, Tausendschön M, Essler S, Geis T, Schmid T, Brüne B. IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1aα translation. J Leukoc Biol. 2014;95(1):129-37.
21. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J. 2005;386:461-70.
22. Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J. 2004;23(19):3780-92.
23. Tausendschön M, Rehli M, Dehne N, Schmidl C, Döring C, Hansmann M-L, et al. Genome-wide identification of hypoxia-inducible factor-1 and-2 binding sites in hypoxic human macrophages alternatively activated by IL-10. Biochim Biophys Acta. 2015;1849(1):10-22.
24. Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, Kahari VM, et al. Hypoxia-activated Smad3-specific Dephosphorylation by PP2A. J Biol Chem. 2009;285(6):3740-9.
25. Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M, et al. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor β signaling. Mol Cell Biol. 2009;29(1):172-86.
26. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Böttinger EP, et al. TGF-β induces proangiogenic and antiangiogenic factorsvia parallel but distinct Smad pathways1. Kidney Int. 2004;66(2):605-13.
27. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, et al. Functional characterization of transforming growth factor β signaling in Smad2-and Smad3-deficient fibroblasts. J Biol Chem. 2001;276(23):19945-53.
28. Lo RS, Massagué J. Ubiquitin-dependent degradation of TGF-β activated Smad2. Nat Cell Biol. 1999;1(8):472-8.
29. Goll DE, Thompson VF, Li H, Wei W, CONG J. The calpain system. Physiol Rev. 2003;83(3):731-801.
30. Deshpande RV, Goust J-M, Chakrabarti AK, Barbosa E, Hogan EL, Banik NL. Calpain expression in lymphoid cells increased mRNA and protein levels after cell activation. J Biol Chem. 1995;270(6):2497-505.
31. Walker G, Pfeilschifter J, Otten U, Kunz D. Proteolytic cleavage of inducible nitric oxide synthase (iNOS) by calpain I. Biochim Biophys Acta. 2001;1568(3):216-24.
32. Zheng X, Zhou A-X, Rouhi P, Uramoto H, Borén J, Cao Y, et al. Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response. Proc Natl Acad Sci. 2014;111(7):2560-5.
33. Iwamoto H, Miura T, Okamura T, Shirakawa K, Iwatate M, Kawamura S, et al. Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart. J Cardiovasc Pharmacol. 1999;33(4):580-6.
34. Zhang J, Patel JM, Block ER. Hypoxia-specific upregulation of calpain activity and gene expression in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 1998;275(3):L461-8.
35. Tyagi T, Ahmad S, Gupta N, Sahu A, Ahmad Y, Nair V, et al. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood. 2014;123(8):1250-60.
36. Zimmerman UJP, Boring L, Pak UH, Mukerjee N, Wang KK. The calpain small subunit gene is essential: its inactivation results in embryonic lethality. IUBMB Life. 2000;50(1):63-8.
37. Zhou J, Köhl R, Herr B, Frank R, Brüne B. Calpain mediates a von hippel-lindau protein-independent destruction of hypoxia-inducible factor-1aα. Mol Biol Cell. 2006;17(4):1549-58.
38. Muldoon LL, Rodland K, Magun B. Transforming growth factor beta and epidermal growth factor alter calcium influx and phosphatidylinositol turnover in rat-1 fibroblasts. J Biol Chem. 1988;263(35):18834-41.
39. Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilágyi A, Bánóczi Z, et al. On the sequential determinants of calpain cleavage. J Biol Chem. 2004;279(20):20775-85.
40. Ono Y, Sorimachi H, Mamitsuka H. Calpain cleavage prediction using multiple kernel learning. PLoS One. 2011;6(5):e19035.
41. Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904-12.
42. LaGamba D, Nawshad A, Hay ED. Microarray analysis of gene expression during epithelial-mesenchymal transformation. Dev Dyn. 2005;234(1):132-42.
43. Kretschmer A, Moepert K, Dames S, Sternberger M, Kaufmann J, Klippel A. Differential regulation of TGF-β signaling through Smad2, Smad3 and Smad4. Oncogene. 2003;22(43):6748-63.
44. Petersen M, Pardali E, Van Der Horst G, Cheung H, Van Den Hoogen C, Van Der Pluijm G, et al. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 2009;29(9):1351-61.
45. Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 2008;68(17):7090-9.
46. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biol. 2015. doi: 10.1016/j.matbio.2015.04.004.
47. Jiang W, Sanders A, Katoh M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015. doi: 10.1016/j.semcancer.2015.03.008.
48. Shapiro S, Khodalev O, Bitterman H, Auslender R, Lahat N. Different activation forms of MMP-2 oppositely affect the fate of endothelial cells. Am J Physiol Cell Physiol. 2010;298(4):C942-51.
49. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res. 2002;90(7):784-91.
50. Chowdhury UR, Samant RS, Fodstad O, Shevde LA. Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Rev. 2009;28(1-2):225-32.
51. Zawel L, Le Dai J, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1(4):611-7.
52. Jennewein C, Kuhn A-M, Schmidt MV, Meilladec-Jullig V, von Knethen A, Gonzalez FJ, et al. Sumoylation of peroxisome proliferator-activated receptor γ by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from ΚB binding sites mediating transrepression of proinflammatory cytokines. J Immunol. 2008;181(8):5646-52.